TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03321019

Intervention type: DRUG
Intervention: Capsaicin
Description: Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.

Intervention type: DRUG
Intervention: Capsaicin
Description: Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.

Intervention type: DEVICE
Intervention: Resistive respiratory loads
Description: Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.

Intervention type: DEVICE
Intervention: Resistive respiratory loads
Description: Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.

Intervention type: OTHER
Intervention: Event-related evoked potential using electroencephalography (EEG).
Description: The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.

Intervention type: OTHER
Intervention: Event-related evoked potential using electroencephalography (EEG).
Description: The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.

Intervention type: PROCEDURE
Intervention: Fluoroscopic swallow evaluation
Description: Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.

Intervention type: PROCEDURE
Intervention: Fluoroscopic swallow evaluation
Description: Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
Study: NCT02068404

Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Study: NCT04716673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
Study: NCT01963676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Study: NCT04313023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for inhalation
Study: NCT02067988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 microspheres hepatic radioembolization.
Description: Holmium-166 microspheres hepatic radioembolization.
Study: NCT00919802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline as a nasal spray
Description: A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
Study: NCT04004273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 24 moderate-intensity exercise training sessions over six weeks (four times per week; \~50 min per session)
Study: NCT04090307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC Group Prenatal Care
Description: TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
Study: NCT00681824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Description: Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
Study: NCT04769128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy programe
Description: thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy programe
Description: thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
Study: NCT02295280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: PO
Study: NCT02184507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement pre CABG
Description: One sachet of the supplement was consumed daily for 7 days before surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement post CABG
Description: One sachet of the supplement was consumed daily for 30 days after surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement pre and post CABG
Description: One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Study: NCT03092089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity, (Lipid Microspheres) Intravenous Suspension
Description: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography
Description: Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repurfusion therapy with PPCI
Description: Patients will receive reperfusion therapy with PPCI as standard of care
Study: NCT01626131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Participants will engage in 3 aerobic and resistance exercise sessions (\~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching training
Description: Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (\~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
Study: NCT03171610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil group
Description: PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl group
Description: PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Study: NCT00769678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the diaphragm
Description: Stimulation of the diaphragm using an electrode
Study: NCT01155284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Lansoprazole
Description: Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~* Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~* Subjects age 18-45 years at Visit 2 will take 2 capsules once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
Study: NCT03438331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Description: The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy for Depression (CBT-D)
Description: The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
Study: NCT03863652

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention via snuffbox approach
Description: After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
Study: NCT02643966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole breast ultrasound
Description: Breast cancer screening with whole breast ultrasound
Study: NCT01794156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inference-based therapy
Study: NCT04498052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening
Description: The intervention will consist of the following core items:~* An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~* Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~Improvements may also be introduced based on user feedback. All major enhancements will be introduced with the support and approval of the appropriate governance group.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption.
Study: NCT02962531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 caplets 1600 mg (4 x 400 mg), fasted
Description: oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 caplets 1600 mg (4 x 400 mg), fed
Description: oral dose under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 aqueous dispersion 1600 mg (20 mL), fasted
Description: oral dose under fasted conditions
Study: NCT01246973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
Study: NCT01355523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (N-acetyl-5-methoxytryptamine)
Description: 6 mg oral melatonin daily 1 hour before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 mg oral placebo daily 1 hour before bedtime
Study: NCT05437484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led BASICS
Description: The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol.
Study: NCT02740673

Intervention type: DEVICE
Group type: OTHER
Intervention: Driving simulator
Description: Patients are asked to use a driving simulator to test their driving skills
Study: NCT02169531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ex vivo Activated Immune Cells
Description: The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
Study: NCT02407028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (1.5 ATA, no NBH)
Description: HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.0 ATA, no NBH)
Description: HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.5 ATA, no NBH)
Description: HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (1.5 ATA + NBH)
Description: HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.0 ATA + NBH)
Description: HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2.5 ATA + NBH)
Description: HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia (NBH)
Description: 100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
Study: NCT04519229

Intervention type: BEHAVIORAL
Intervention: Child-Parent Psychotherapy
Description: Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
Study: NCT04543929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: partially supervised and home-based exercise activity
Study: NCT03473886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: PP-MI
Description: The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
Study: NCT02407028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Will be treated with usual and customary care for severe traumatic brain injury
Study: NCT01667965

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
Study: NCT00363129

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01589029

Intervention type: DRUG
Group type: OTHER
Intervention: CANAKINUMAB (ILARIS®)
Description: subcutaneous injection every 8 weeks
Study: NCT01252836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWBAT-D
Description: Application of AWBAT-D bioengineered device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AWBAT-D
Description: Application of AWBAT-D bioengineered device
Study: NCT02868905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Study: NCT03818919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Traditionally used narcotic pain protocol